Daniel Wilson MD

Dr. Wilson received his Doctor of Medicine at Rush Medical University in 1974 and completed postgraduate training in Internal Medicine, Hypertension, and Nephrology, and a Renal Research Fellowship at the Cleveland Clinic Foundation in 1979. He has held academic and clinical appointments at Cleveland Clinic Foundation, Bowman Gray School of Medicine - Wake Forest University, and at the Mayo Clinic -- Mayo Medical School.

Dr. Wilson joined Pfizer Global Pharmaceuticals in 2001 as a Cardiovascular Regional Medical Research Specialist (RMRS). In 2009, he joined the Cardiovascular (Headquarters) Medical Affairs in New York providing strategic support for Lipitor and Caduet. In 2012, Dan accepted a position in clinical development as a Regional Medical Monitor (RMM) and provided medical oversight for high risk clinical trials. In 2013, Dr. Wilson joined The PRECISION Study team as the senior study clinician with global responsibility for the trial. Dr. Wilson actively monitored patient safety, and managed quality assessment, investigator relations, subject retention initiatives, and endpoint and adjudication confirmation, for the 24,000-patient study.

Dan joined Relypsa, a Vifor company, in 2014 as a senior medical director advancing to executive medical director in medical and scientific affairs. Dr. Wilson participated in the clinical development and the launch of patiromer (Veltassa) in 2016 and authored several scientific publications. Dan developed and lead the Global Hyperkalemia Council, group of 20 cardiology and nephrology KOLs responsible for the development of new strategic scientific platforms.

In 2018, Dr. Wilson joined KBP Biosciences as a senior vice president for clinical development, and the medical lead for the Phase IIb BLOCK/CKD trial. Dan initiated, authored and implemented a comprehensive protocol amendment designed to improve/facilitate patient recruitment, reduce administrative burden at trail sites, improve patient safety monitoring, and to improve the scientific rigor of the study.

Dr. Wilson joined Bayer Pharmaceuticals in 2020 as senior medical director and cardiorenal strategist and subject matter expert. He has continued to be involved in clinical research on cardiorenal disease and hypertension.